We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Fresenius Medical Care AG | NYSE:FMS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.45 | -6.77% | 19.97 | 20.18 | 19.69 | 19.87 | 287,613 | 16:06:08 |
By Ulrike Dauer
FRANKFURT--Fresenius SE & Co. KGaA (FRE.XE) raised its full-year profit guidance after adjusted net profit rose 12% in the second quarter because of a strong performance at its Fresenius Kabi unit in North America.
Late Monday, Fresenius said it now expects 2016 adjusted net profit to rise between 11% and 14% over the 2015 figure, up from the previously anticipated rise of between 8% and 12%.
Fresenius confirmed its 2016 sales target of growth between 6% and 8%.
Fresenius Kabi, the group's clinical technology provider, also raised its full-year outlook for sales and EBIT. It now expects sales and adjusted EBIT in constant currency to grow between 3% and 5%. Fresenius Kabi reported a net profit rise of 7% to 180 million euros ($201.15 million) for the second quarter.
The group's quarterly adjusted net profit rose to EUR393 million, beating a EUR384 million forecast in a Dow Jones Newswires analyst poll. Earnings before interest and taxes increases 8% to EUR1.05 billion. Sales were up 2% at EUR7.1 billion.
All four business units contributed to the improvements.
Fresenius's biggest unit, Medical Care AG & Co. KGaA (FMS), the world's largest provider of dialysis products and services, reported a 22% rise in net profit to $294 million, on a 5% sales increase to $4.42 billion. It confirmed its full-year guidance.
-Write to Ulrike Dauer at Ulrike.Dauer@wsj.com
(END) Dow Jones Newswires
August 02, 2016 01:39 ET (05:39 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Fresenius Medical Care Chart |
1 Month Fresenius Medical Care Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions